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Effects of different serum conditions on
osteogenic differentiation of human adipose
stem cells in vitro
Laura Kyllönen1,2,3†, Suvi Haimi1,2,3,4*†, Bettina Mannerström1,2,3, Heini Huhtala5, Kristiina M Rajala2,3,6,
Heli Skottman2,3,7, George K Sándor1,2,3,8 and Susanna Miettinen1,2,3
Abstract
Introduction: Currently, human adipose stem cells (hASCs) are differentiated towards osteogenic lineages using
culture medium supplemented with L-ascorbic acid 2-phosphate (AsA2-P), dexamethasone (Dex) and beta-
glycerophosphate (b-GP). Because this osteogenic medium (OM1) was initially generated for the differentiation of
bone marrow-derived mesenchymal stem cells, the component concentrations may not be optimal for the
differentiation of hASCs. After preliminary screening, two efficient osteogenic media (OM2 and OM3) were chosen
to be compared with the commonly used osteogenic medium (OM1). To further develop the culture conditions
towards clinical usage, the osteo-inductive efficiencies of OM1, OM2 and OM3 were compared using human serum
(HS)-based medium and a defined, xeno-free medium (RegES), with fetal bovine serum (FBS)-based medium
serving as a control.
Methods: To compare the osteo-inductive efficiency of OM1, OM2 and OM3 in FBS-, HS- and RegES-based
medium, the osteogenic differentiation was assessed by alkaline phosphatase (ALP) activity, mineralization, and
expression of osteogenic marker genes (runx2A, DLX5, collagen type I, osteocalcin, and ALP).
Results: In HS-based medium, the ALP activity increased significantly by OM3, and mineralization was enhanced by
both OM2 and OM3, which have high AsA2-P and low Dex concentrations. ALP activity and mineralization of
hASCs was the weakest in FBS-based medium, with no significant differences between the OM compositions due
to donor variation. However, the qRT-PCR data demonstrated significant upregulation of runx2A mRNA under
osteogenic differentiation in FBS- and HS-based medium, particularly by OM3 under FBS conditions. Further, the
expression of DLX5 was greatly stimulated by OM1 to 3 on day 7 when compared to control. The regulation of
collagen type I, ALP, and osteocalcin mRNA was modest under induction by OM1 to 3. The RegES medium was
found to support the proliferation and osteogenic differentiation of hASCs, but the composition of the RegES
medium hindered the comparison of OM1, OM2 and OM3.
Conclusions: Serum conditions affect hASC proliferation and differentiation significantly. The ALP activity and
mineralization was the weakest in FBS-based medium, although osteogenic markers were upregulated on mRNA
level. When comparing the OM composition, the commonly used OM1 was least effective. Accordingly, higher
concentration of AsA2-P and lower concentration of Dex, as in OM2 and OM3, should be used for the osteogenic
differentiation of hASCs in vitro.
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Introduction
The osteogenic potential of human adipose stem cells
(hASCs) has recently stimulated interest in clinical bone
tissue engineering [1,2]. This multipotent population of
cells, isolated from the stromal vascular compartment of
adipose tissue, was originally characterized by Zuk and
co-workers [3]. It was soon discovered that hASCs are
able to differentiate toward osteogenic, adipogenic, myo-
genic, and chondrogenic lineages in vitro, when treated
with appropriate inducing factors [3]. Since their discov-
ery, different approaches have been developed to enhance
osteogenic capacity of hASCs. Much of the research has
concentrated on the osteo-induction of hASCs via growth
factors such as bone morphogenetic proteins (BMPs)
[4-6]. Although considerable research has been devoted
to BMPs, their cost-effectiveness and safety in clinical use
have been under controversy [7-10]. Recent studies have
also questioned whether hASCs are responsive to BMPs
at all [11]. Therefore, efficient methods for osteo-induc-
tion of hASCs are still required.
Commonly, osteogenic differentiation of mesenchymal
stem cells (MSCs) in in vitro culture has been managed
by supplementing the growth medium with 50 µM L-
ascorbic acid 2-phosphate (AsA2-P), 100 nM dexa-
methasone (Dex) and 10 mM beta-glycerophosphate (b-
GP) [11-14]. Because this osteogenic medium (OM) was
initially generated for the differentiation of bone mar-
row-derived mesenchymal stem cells (BMSCs) [15], the
component concentrations may not be optimal for the
differentiation of hASCs [16]. Although BMSCs and
ASCs possess many similar characteristics, their
response to inductive stimuli may not be identical
[12,17,18]. Whereas the combined and separate effects
of Dex and AsA2-P have been largely studied with
BMSCs [15,19-21], there are only limited studies with
hASCs [16,22]. For example, de Girolamo and co-work-
ers suggested that OM with lower Dex and higher
AsA2-P concentration could be more effective with
hASCs than the commonly used OM [16]. However,
this study was conducted using two donor cell lines and
more importantly only fetal bovine serum (FBS)-con-
taining medium. Therefore, we conducted a preliminary
screening using different osteogenic supplement concen-
trations in human serum (HS)-based medium. Based on
these preliminary results, two efficient compositions
(OM2 and OM3) were chosen for further comparison in
different serum conditions with the commonly used
OM (referred here as OM1).
So far, the effects of OM on hASC differentiation have
been defined mostly using FBS-containing medium
[12,13,16]. While FBS-based medium may be acceptable
for the in vitro experiments, exposure to undefined ani-
mal-derived products poses a risk in clinical stem cell
therapies [23,24]. Replacing animal-derived products
such as FBS with human serum, human platelet lysate,
platelet-rich plasma or defined xeno-free alternative, sig-
nificantly enhances the safety and quality of stem cells
for therapeutic approaches [23,25]. In addition to safety
issues, serum conditions can have a significant effect on
stem cell characteristics such as differentiation capacity
and proliferation [26,27]. In order to define how serum
conditions affect the osteogenic differentiation of
hASCs, we tested HS-based medium and a defined,
xeno-free medium (RegES) in comparison to FBS-based
medium to evaluate the efficiency of three different OM
compositions. The fully defined xeno-free medium for-
mulation RegES was previously developed in our insti-
tute for stem cell culture [28].
In order to produce clinically relevant in vitro data the
effects of three different OM compositions on hASCs




This study was conducted in accordance with the Ethics
Committee of the Pirkanmaa Hospital District, Tampere,
Finland (R03058), to obtain adipose tissue samples for
research purposes. The hASCs were isolated from adi-
pose tissue samples acquired from surgeries performed
in the Department of Plastic Surgery, Tampere Univer-
sity Hospital. The subcutaneous adipose tissue samples
harvested from either abdomen or breast were obtained
with a written informed consent from six female donors
(mean age 53 ± 16).
Isolation and cell culture
Human ASCs were isolated from adipose tissue samples
by mechanical and enzymatic method as described pre-
viously [26,29]. Briefly, the adipose tissue samples were
minced into smaller pieces and digested with collage-
nase type I (1.5 mg/ml; Invitrogen, Carlsbad, CA, USA),
followed by centrifugation and filtering steps. The iso-
lated hASCs were maintained and expanded in mainte-
nance medium (MM) consisting of Dulbecco’s modified
Eagle’s medium/Ham’s Nutrient Mixture F-12 (DMEM/
F-12 1:1; Invitrogen) supplemented with 1% L-alanyl-L-
glutamine (GlutaMAX; Invitrogen), 1% antibiotics (100
U/ml penicillin, 0.1 mg/ml streptomycin; Invitrogen),
and either 10% allogeneic HS (PAA Laboratories GmbH,
Pasching, Austria) (referred as HS MM) or 10% FBS
Gold (PAA Laboratories) (referred as FBS MM). FBS
Gold was used for the experiments, because it has been
reported to eliminate the need for extensive and time-
consuming batch testing due to its constant quality. The
hASCs from each donor were isolated into both HS and
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FBS maintenance medium. The hASCs isolated and
expanded in HS medium were detached using TrypLE
Select (Life Technologies, Carlsbad, CA, USA), whereas
hASCs in FBS medium were detached using 1% trypsin
(Lonza Biowhittaker, Verviers, Belgium). For xeno-free
conditions, hASCs were first isolated and expanded in
HS MM, and xeno-free RegES medium was added after
hASCs were seeded onto well plates. The composition
of RegES maintenance medium (RegES MM) is shown
in Additional file 1. A CELLstart (Invitrogen) pre-coat-
ing of polystyrene well plates was required for the cell
attachment under RegES conditions. The experiments
were carried out at passages three to four.
Characterization of the cells
In order to verify the mesenchymal origin, hASCs must
meet several criteria defined by the International Society
for Cellular Therapy [30]. The mesenchymal origin of
hASCs used in this study was confirmed by their adher-
ence to plastic, differentiation capacity to osteogenic,
chondrogenic and adipogenic lineages in vitro, and by
their surface marker expression.
Flow cytometric surface marker expression analysis
Flow cytometry was used to characterize the surface
marker expression of hASCs cultured in FBS and HS
MM. Flow cytometric characterization comparing the
surface marker expression of hASCs cultured in HS
medium and xeno-free RegES medium has been
reported previously [28]. Briefly, hASCs cultured in FBS
and HS MM were analyzed by a fluorescence-activated
cell sorter (FACSAria; BD Biosciences, Erembodegem,
Belgium) as described by Lindroos and co-workers [26].
Monoclonal antibodies against CD14-PE, CD19-PE,
CD49d-PE, CD73-PE, CD90-APC, CD106-PE, (BD Bios-
ciences); CD45-FITC (Miltenyi Biotech, Bergisch Glad-
bach, Germany); CD34-APC, HLA-ABC-PE, HLA-DR-
PE (Immunotools GmbH Friesoythe, Germany); and
CD105-PE (R&D Systems Inc, Minneapolis, MN, USA)
were used. Analysis was performed on 10,000 cells per
sample and unstained cell samples were used to com-
pensate for the background autofluorescence levels.
Analysis of multipotent differentiation capacity
The multipotent differentiation of hASCs was conducted
in RegES medium supplemented with corresponding
adipogenic, osteogenic and chondrogenic components.
The multipotent differentiation capacity of hASCs cul-
tured in FBS and HS medium has been shown pre-
viously by Lindroos and co-workers [31].
For multipotency analysis, CELLstart pre-coating was
used for well plates in all differentiation procedures
except for chondrogenic differentiation. For osteogenic
induction analysis, hASCs were seeded on 12-well plates
at a density of 2.5 × 103 cells/cm2 in HS MM. After 24
hours, the HS medium was replaced by OM3 in RegES
medium (Table 1). The osteogenic differentiation was
detected by alkaline phosphatase (ALP) staining at a 14-
day time point. Briefly, cell cultures were fixed with 4%
paraformaldehyde (PFA) and stained with a leukocyte
ALP kit according to Sigma procedure 86 (Sigma-
Aldrich, St Louis, MO, USA).
For the adipogenic induction, hASCs were seeded on
12-well plates at a density of 2 × 104 cells/cm2 in HS
MM. After 2 days, RegES medium with adipogenic sup-
plements was added: 33 µM biotin (Sigma-Aldrich), 1
µM Dex (Sigma-Aldrich), 100 nM insulin (Life Technol-
ogies), and 17 µM pantothenate (Fluka, Buchs, Switzer-
land). In addition to other adipogenic supplements, 250
µM isobutylmethylxanthine (IBMX; Sigma-Aldrich) was
used for the first 24 hours of adipogenic induction.
After 14 days of culture, the intracellular lipid accumu-
lation was detected by Oil Red O staining. Cell cultures
were fixed with 4% PFA, followed by treatment with
60% isopropanol, and stained with 0.5% Oil Red O solu-
tion (Sigma-Aldrich) in 60% isopropanol.
A micromass culture technique was used for the chon-
drogenic differentiation, where 1 × 105 cells were seeded
on 24-well plates in a 10 µl volume, and allowed to
adhere for 3 hours in +37°C prior to the addition of
RegES medium with chondrogenic supplements: 1% ITS
+1 (Sigma-Aldrich), 50 µM AsA2-P (Sigma-Aldrich), 55
µM sodium pyruvate (Life Technologies), 23 µM L-pro-
line (Sigma-Aldrich), 10 ng/ml transforming growth
factor-beta (Sigma-Aldrich). The chondrogenic differen-
tiation was confirmed by histological Alcian Blue (Sigma-
Aldrich) staining after 14 days of culture. The micromass
pellets were fixed in 4% PFA, embedded in paraffin and
sectioned at 5 µm thickness. Alcian Blue (pH 1.0) solu-
tion was used to detect sulphated glycosaminoglycans
(GAGs) characteristic in cartilaginous matrices. Nuclear
Fast Red (Biocare Medical, Concord, MA, USA) was used
as a counterstain.




10% FBS-, 10% HS-, or RegES-medium
OM1 100 nM Dex, 50 µM AsA2P, 10 mM b-GP in MM
OM2 10 nM Dex, 150 µM AsA2P, 10 mM b-GP in MM
OM3 5 nM Dex, 250 µM AsA2P, 10 mM b-GP in MM
Maintenance medium (MM) was culture medium with 10% FBS or 10% HS, or
defined, xeno-free RegES-medium (composition defined in Additional file 1).
The osteogenic media (OM) were supplemented with dexamethasone (Dex),
L-ascorbic acid 2-phosphate (AsA2-P), and beta-glycerophosphate (b-GP). MM,
maintenance medium; OM, osteogenic medium; FBS, fetal bovine serum; HS,
human serum; Dex, dexamethasone; AsA2-P, L-ascorbic acid 2-phosphate; b-
GP, beta-glycerophosphate.
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Osteogenic medium compositions
For the comparison of the different OM compositions,
hASCs were plated on 12-well plates at a density of 7 ×
103 cells/cm2. The cells were plated in either HS or FBS
MM and allowed to attach for 24 hours before starting
the osteogenic differentiation. For xeno-free conditions,
the well plates were pre-coated with CELLstart and
hASCs were plated in HS MM for 24 hours to facilitate
attachment of the cells before medium was replaced by
RegES MM or RegES with osteogenic supplements
(Table 1). Three different osteogenic medium composi-
tions, OM1, OM2 and OM3, were compared in FBS, HS
and xeno-free conditions (Table 1). Based on the litera-
ture, OM with lower Dex and higher AsA2-P concentra-
tion than in the traditionally used OM (OM1) was
suggested to be more optimal for osteo-induction of
hASCs in FBS-based medium [16]. We conducted a pre-
liminary screening to test different concentrations of
AsA2-P and Dex in HS-based medium (Additional file
2). Based on these results, OM2 and OM3 with low Dex
and high AsA2-P concentrations were chosen for further
comparison with the traditionally used OM1. AsA2-P,
Dex and b-GP used in the osteogenic media were all
purchased from Sigma-Aldrich. The hASCs cultured in
FBS MM were used as a reference in all the analyses. It
must be noted that RegES MM contains a high basal
level of AsA2-P (50 µg/ml that corresponds to 170 µM).
As a consequence, the additional AsA2-P in the osteo-
genic compositions raised the total concentrations of
AsA2-P in RegES-based OM1, OM2 and OM3 to 220,
320, and 420 µM, respectively.
Morphology and cell number
Cell number, based on the total amount of DNA per
sample, was determined using a CyQUANT™ Cell Pro-
liferation Assay Kit (CyQUANT; Molecular Probes, Invi-
trogen, Paisley, UK) as described previously [32]. Briefly,
at 1-, 7- and 14-day time points the cells were lysed
with 0.1% Triton-X 100 buffer (Sigma-Aldrich) and ana-
lyzed after a freeze-thaw cycle. Fluorescence was mea-
sured with a microplate reader (Victor 1420 Multilabel
Counter; Wallac, Turku, Finland) at 480/520 nm.
Morphology of the cells was observed at 1-, 3-, 7- and
14-day time points using light microscopy.
Alkaline phosphatase activity and mineralization
The osteogenic differentiation capacity of hASCs was
determined at 7 and 14 days by analyzing ALP activity
and mineralization. ALP is a generally used marker for
early osteogenic differentiation, whereas mineralization
of the ECM is a characteristic of late osteogenic differ-
entiation. The quantitative ALP analysis was performed
on the same samples as the analysis of cell number,
using the ALP Kit (Sigma-Aldrich) as reported
previously [32]. A quantitative Alizarin Red S method
was used at 7 and 14 days to detect mineralization as
described previously [32]. Briefly, the ethanol fixed cells
were stained with 2% Alizarin Red S solution (Sigma-
Aldrich), and photographed after several steps of wash-
ing. Cetylpyridinium chloride (Sigma-Aldrich) was used
to extract the dye, followed by absorbance measurement
at 540 nm with a microplate reader (Victor 1420).
Quantitative real-time PCR
Quantitative real-time reverse transcription polymerase
chain reaction (qRT-PCR) analysis was used to compare
the relative expression of osteogenic genes under differ-
ent culturing conditions. For qRT-PCR analysis, hASCs
were seeded on 6-well plates at a density of 7 × 103
cells/cm2. A CELLstart pre-coating of well plates was
used in xeno-free conditions. Total RNA was isolated
from the cells at 7- and 14-day time points with
Nucleospin kit reagent (Macherey-Nagel GmbH & Co.
KG, Düren, Germany) according to manufacturer’s
instructions. First-strand cDNA was synthesized from
total RNA using the High-Capacity cDNA Reverse
Transcriptase Kit (Applied Biosystems, Foster City, CA,
USA). The expression of osteogenic genes including
runx2A, DLX5, collagen type I, osteocalcin, and ALP
was analyzed. Isoform A of runx2 was analyzed due to
its specificity for osteogenic differentiation in compari-
son to isoform C [33,34]. Data was normalized to the
expression of RPLP0 (human acidic ribosomal phospho-
protein P0), a housekeeping gene, which has shown to
have stable expression under different experimental con-
ditions in similar studies [35,36]. The primer sequences
(Oligomer Oy, Helsinki, Finland) and accession numbers
are presented in Table 2. The qRT-PCR mixture con-
tained 50 ng cDNA, 300 nM forward and reverse pri-
mers, and SYBR Green PCR Master Mix (Applied
Biosystems). The reactions were conducted with AbiPr-
ism 7000 Sequence Detection System (Applied Biosys-
tems) with initial enzyme activation at 95°C for 10
minutes, followed by 45 cycles of denaturation at 95°C
for 15 seconds and anneal and extend at 60°C for 60
seconds. The expression levels of all differentiation cul-
tures were compared to the expression level of FBS con-
trol cultures.
Statistical analysis
Statistical analyses were performed with SPSS version 19
(IBM, Armonk, NY, USA). The effects of different cul-
ture conditions on cell number, normalized ALP activ-
ity, mineralization and relative gene expression were
compared with nonparametric statistics using Kruskal-
Wallis one-way analysis of variance by ranks, with
Mann-Whitney post hoc test to analyze the specific
sample pairs for significant differences. The significances
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obtained were corrected using Bonferroni adjustment in
order to justify multiple comparisons. For example, the
obtained P value was multiplied by the comparisons
made within the time point (MM vs. OM1/OM2/OM3,
OM1 vs. OM2/OM3, and OM2 vs. OM3 equals six
comparisons within one time point), and multiplied with
the number of time points (6 × 3 time points = 18, or 6
× 2 time points = 12). When for example P = 0.002 was
obtained with Mann-Whitney, the P value was multi-
plied with 12 or 18, giving the final P values 0.024 or
0.036 respectively, depending the number of time points.
The results were considered significant when P <0.05.
The effect of culture duration on cell number was ana-
lyzed similarly using Kruskal-Wallis, Mann-Whitney and
Bonferroni adjustment as described. All the results were
standardized to the control condition (FBS MM). All the
experiments were repeated three times using different
donor in each repeat (n = 3). Technical triplicates of
each sample were used in all the assays.
Results
Flow cytometric surface marker expression analysis
The flow cytometric analysis demonstrated that hASCs
cultured in FBS and HS MM express the surface mar-
kers CD73, CD90, CD105 (Table 3). The hASCs lacked
the expression of the CD14, CD19, HLA-DR, the hema-
topoietic marker CD45, and the vascular cell adhesion
molecule CD106. The expression of CD34, CD49d and
HLA-ABC was moderate. The results verified the
mesenchymal origin of the hASCs, and the lack of
hematopoietic and angiogenic markers [26,37,38].
Analysis of multipotent differentiation capacity
The multipotent differentiation capacity of the hASCs
cultured in RegES was examined by culturing the cells
under osteogenic, adipogenic and chondrogenic
conditions (Figure 1A-C). Differentiation was analyzed
by histological stainings at a 14-day time point. Osteo-
genic differentiation was confirmed by a positive ALP
staining at day 14 (Figure 1A). Adipogenic differentia-
tion (Figure 1B) was verified by Oil Red O staining,
showing the lipid droplets present in differentiated cells.
Chondrogenic differentiation (Figure 1C) was confirmed
by the formation of aggregates as well as Alcian Blue
staining. The chondrogenically induced hASCs formed
aggregates that were intensively stained by Alcian Blue,
Table 2 The primer sequences for qRT-PCR.
Name 5’- Sequence -3’ Product size (bp) Accession number
RUNX2A Forward CTTCATTCGCCTCACAAACAAC 62 NM_001024630.3
Reverse TCCTCCTGGAGAAAGTTTGCA
DLX5 Forward ACCATCCGTCTCAGGAATCG 75 NM_005221.5
Reverse CCCCCGTAGGGCTGTAGTAGT
Collagen type I Forward CCAGAAGAACTGGTACATCAGCAA 94 NM_00088
Reverse CGCCATACTCGAACTGGAATC
Osteocalcin Forward AGCAAAGGTGCAGCCTTTGT 63 NM_000711
Reverse GCGCCTGGGTCTCTTCACT
Alkaline phosphatase Forward CCCCCGTGGCAACTCTATCT 73 NM_000478.4
Reverse GATGGCAGTGAAGGGCTTCTT
RPLP0 Forward AATCTCCAGGGGCACCAT T 70 NM_001002
Reverse CGCTGGCTCCCACTTTGT
Table 3 Characterization of hASCs.
Antigen Surface protein FBS HS
CD14 Serum lipopolysaccharide-
binding protein
2.6 ± 2.7 1.1 ± 1.0
CD19 B lymphocyte-lineage
differentiation antigen
1.1 ± 0.9 0.4 ± 0.1
CD34 Sialomucin-like adhesion
molecule
19.6 ± 12.2 27.4 ± 23.5
CD45 Leukocyte common antigen 1.5 ± 0.8 1.8 ± 1.6
CD49d Integrin a2, VLA-4 12.7 ± 2.5 35.4 ± 10.1
CD73 Ecto-50-nucleotidase 82.2 ± 8.5 85.9 ± 7.3
CD90 Thy-1 (T cell surface
glycoprotein)
97.3 ± 2.5 96.5 ± 4.6
CD105 SH-2, endoglin 85.3 ± 17.7 79.2 ± 21.1
CD106 VCAM-1 (vascular cell
adhesion molecule)
0.6 ± 0.3 1.3 ± 1.7
HLA-ABC Major histocompatibility class
I antigens
16.9 ± 8.1 28.1 ± 16.4
HLA-DR Major histocompatibility class
II antigens
1.9 ± 1.2 1.0 ± 1.0
Surface marker expression of undifferentiated hASCs cultured either in FBS- or
HS-medium as analyzed by flow cytometric analysis. Data is presented as
mean ± standard deviation of the percentage of surface marker expression (n
= 6). hASCs, human adipose stem cells; FBS, fetal bovine serum; HS, human
serum; CD, cluster of differentiation.
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indicating the presence of sulphated GAGs typical to
cartilage.
Preliminary screening of the osteogenic medium
compositions
Preliminary screening was conducted to test a hypoth-
esis if OM with low Dex and high AsA2-P concentra-
tions could be efficient osteo-inducer of hASCs in HS-
based medium (Additional file 2). According to the pre-
liminary screening, it was concluded that AsA2-P is
needed for the effective osteogenic differentiation of
hASCs, and higher concentrations of AsA2-P resulted in
increased runx2 expression and ALP activity (data not
shown). Dex was found to suppress proliferation and
collagen type I expression at high concentration (100
nM), whereas low Dex concentration (5 nM) was benefi-
cial for the osteogenic differentiation when combined
with high AsA2-P concentration (250 µM). Conse-
quently, the highest proliferation, ALP activity and
runx2 expression were achieved with 150 µM AsA2-P
and 10 nM Dex (OM2), and 250 µM AsA2-P and 5 nM
Dex (OM3), compositions that were selected for further
experiments to be compared with the traditionally used
composition (OM1), containing 50 µM AsA2-P and 100
nM Dex.
Morphology and cell number
Cell number was analyzed quantitatively at 7- and 14-
day time points (Figure 2) along with observation of
morphology (Figure 3 and Additional file 3). Cell num-
ber was also analyzed at day 1 to test for equal plating
efficiency; this was confirmed by the similar cell num-
bers between FBS, HS and RegES conditions at day 1
(data not shown). All different maintenance media were
able to support the proliferation of hASCs as the cell
numbers increased significantly (P <0.05) with time
when comparing day 1 and 14 within each serum condi-
tion. However, FBS MM and HS MM exhibited notably
lower cell numbers than RegES MM (Figure 2). The
increased growth rate of hASCs cultured in RegES MM
was evident already after 7 days of culture, as was
shown by cell number (Figure 2) and morphology analy-
sis (Additional file 3). The cell number of RegES main-
tenance culture was significantly higher at day 14 (P
<0.05) when compared to HS and FBS maintenance
cultures.
All osteogenic media (OM1-3) increased cell number
significantly when compared to the respective MM
under HS and RegES conditions at day 14 (Figure 2).
Although a similar trend could be detected in FBS med-
ium at day 14 in Figure 2 and Figure 3, the difference
between MM and OM compositions was not significant
in the quantitative analysis. In contrast, the stimulating
effect of OM in HS and RegES cultures was shown
already at day 7; OM3 exhibited significantly higher cell
number than OM1 and MM in both HS and RegES. At
day 14, in HS cultures the cell number was significantly
higher in OM2 and OM3 when compared to OM1 and
MM. In RegES cultures all OM compositions resulted in
higher cell number than MM at the 14-day time point,
but there were no differences between OM1, OM2 or
OM3. This may be due to the high growth rate of
hASCs in RegES medium; the cells had already reached
confluency by day 14 and grew in multiple layers (Figure
3).
Alkaline phosphatase activity
The ALP activity of each sample was normalized to the
amount of DNA in the sample, and all the results were
considered relative to FBS MM at the 7-day time point.
Due to notable donor variation, ALP activity is pre-
sented as a scatter plot showing the response of
Figure 1 Representative images showing the multilineage differentiation potential of hASCs cultured in RegES medium. ALP staining
for the osteogenic differentiation (A), Oil Red O staining for the adipogenic differentiation (B), and Alcian Blue staining for the chondrogenic
differentiation (C) of hASCs. Scale bar 500 µm in (A), and 100 µm in (B) and (C). ALP, alkaline phosphatase; hASCs, human adipose stem cells.
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Figure 2 Relative cell number. Cell number at day 7 and 14 after culture in maintenance medium (MM) or different osteogenic media (OM1,
OM2 or OM3) based on FBS, HS or RegES. Results are expressed as mean + SD. All results were standardized to the control condition (FBS MM
at day 1). (A) (P <0.05) relative to HS MM; (B) (P <0.05) relative to HS MM and OM1; (C) (P <0.05) relative to RegES MM and OM1; (D) (P <0.05)
relative to RegES OM1, OM2 and OM3, as well as HS MM and FBS MM. FBS, fetal bovine serum; HS, human serum; MM, maintenance medium;
OM, osteogenic medium; SD, standard deviation.
Figure 3 Cell morphology in different media. Representative light microscope images showing hASC morphology and proliferation at 14-day
time point in each medium. Scale bar 500 µm. FBS, fetal bovine serum; hASCs, human adipose stem cells; HS, human serum; MM, maintenance
medium; OM, osteogenic medium
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individual donors at day 14 (Figure 4). There were no
statistically significant differences at day 7 (data not
shown). At day 14, the ALP activity was notably low in
all FBS cultures when compared to HS and RegES cul-
tures. Two out of three donors exhibited a notable
increase of ALP activity in response to OM2 and OM3
under FBS and HS conditions, whereas one donor did
not seem to respond to any of the OM compositions. In
RegES medium, the osteogenic supplements resulted in
higher ALP activity with hASCs from two donors,
whereas one donor line was induced by the RegES MM.
Irrespective of the donor variation, the mean ALP activ-
ity of HS OM3 was significantly higher than with HS
MM (P = 0.036) and OM1 (P = 0.006).
Mineralization
Similar to the ALP activity, OM3 increased mineraliza-
tion the most in FBS cultures at day 14, but the differ-
ence to MM was not significant (Figure 5). Overall,
mineralization was very weak under FBS conditions
(Figures 5 and 6). In HS cultures, OM2 and OM3
resulted in a significantly higher mineralization than
MM and OM1 at the 14-day time point. Although the
difference between OM2 and OM3 in HS was not sig-
nificant in the quantitative analysis of mineralization,
the qualitative Alizarin Red staining showed more
intense mineralization by OM3 than OM2 (Figure 6). In
RegES cultures, all OM compositions induced signifi-
cantly higher mineralization than RegES MM after 14
days of culture (Figures 5 and 6), but there were no sig-
nificant differences between the different OM (Figure 5).
Expression of osteogenic markers
Quantitative RT-PCR was used to detect relative
changes in the expression of osteogenic marker genes
runx2A, DLX5, collagen type I, osteocalcin, and ALP
(Figure 7). The relative expression of runx2A, one of the
key osteogenic transcription factors, was significantly
Figure 4 Relative ALP activity on day 14. The scatter plot shows mean ALP activity for each condition and individual data points for each
donor. All results were standardized to the control condition (FBS MM at day 7). (A) (P <0.05) for the difference between HS OM3 and MM; (B)
(P <0.01) for the difference between HS OM3 and OM1. ALP, alkaline phosphatase; FBS, fetal bovine serum; HS, human serum; MM, maintenance
medium; OM, osteogenic medium.
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Figure 5 Relative mineralization. Quantitative mineralization of hASCs cultured in maintenance medium (MM) or different osteogenic media
(OM1, OM2 or OM3) based on FBS, HS or RegES. Results are expressed as mean + SD. All results were standardized to the control condition
(FBS MM at day 7). (A) (P <0.05) relative to HS MM; (B) (P <0.05) relative to HS MM and OM1; (C) (P <0.05) relative to RegES OM1, OM2 and
OM3. FBS, fetal bovine serum; hASCs, human adipose stem cells; HS, human serum; MM, maintenance medium; OM, osteogenic medium; SD,
standard deviation.
Figure 6 Qualitative mineralization. Representative images showing Alizarin Red staining to detect mineralization of hASCs cultured in
maintenance medium (MM) or different osteogenic media (OM1, OM2 or OM3) based on FBS, HS or RegES at 14-day time point. Scale bar 500
µm. FBS, fetal bovine serum; hASCs, human adipose stem cells; HS, human serum; MM, maintenance medium; OM, osteogenic medium.
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induced by the osteogenic components in FBS and HS
conditions. In FBS cultures, all OM compositions
induced significantly higher expression of runx2A than
MM at the 7-day time point. At day 14, FBS OM3 (P =
0.048) showed significantly higher expression of runx2A
mRNA when compared to FBS MM. In HS cultures, all
OM compositions exhibited significantly higher runx2A
expression than HS MM (P = 0.024) at day 7, and OM3
upregulated the runx2A expression significantly when
compared to OM1. At day 14, a high expression of
Figure 7 Quantitative real-time PCR results. The relative expression of osteogenic genes in hASCs cultured in maintenance medium (MM) or
different osteogenic media (OM1, OM2 or OM3) based on FBS, HS or RegES at 7- and 14-day time points. Results are expressed as mean + SD.
All results were standardized to the control condition (FBS MM at day 7). (A) (P <0.05) relative to FBS MM; (B) (P <0.05) relative to HS MM; (C) (P
<0.05) relative to HS MM and OM1; (D) (P <0.05) relative to FBS MM and OM1; (E) (P <0.05) relative to FBS OM1; (F) (P <0.05) relative to HS OM1
and OM2; (G) (P <0.05) relative to RegES OM1. FBS, fetal bovine serum; hASCs, human adipose stem cells; HS, human serum; MM, maintenance
medium; OM, osteogenic medium; SD, standard deviation.
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runx2A was achieved by HS OM3, but due to donor
variation there was no significant difference to HS MM.
In RegES cultures, there were no statistically significant
differences between the OM compositions and MM for
the expression of runx2A, likely due to the high basal
level of runx2 expression in RegES MM. The expression
of DLX5, activator of runx2, was significantly upregu-
lated by all OM compositions on day 7 under FBS con-
ditions, when compared to FBS MM (P = 0.024).
However, there were no significant differences on day
14. The level of DLX5 expression was low under HS
and RegES conditions.
The expression of collagen type I, a major component
of organic bone matrix, was significantly increased by
OM2 and OM3 under FBS conditions, specifically at day
7 when compared to both MM and OM1. At day 14,
the expression of collagen type I level was slightly lower,
but yet the expression was significantly higher with
OM2 and OM3 than OM1 (P = 0.024). There were no
significant differences between the groups under HS and
RegES conditions. The level of collagen type I mRNA
was generally lower in RegES than in FBS or HS
conditions.
In contrast to collagen, the expression of ALP was
notably upregulated in RegES MM, OM2 and OM3 cul-
tures when compared to FBS and HS cultures at the 14-
day time point. Overall, the level of ALP expression was
low in FBS medium. Nevertheless, significantly higher
expression of ALP mRNA was detected in all FBS OM
compositions at day 7, and by OM2 and OM3 at day
14, when compared to FBS MM (P = 0.024). In HS
medium, OM3 showed significantly higher level of ALP
expression at day 14 than OM1 (P = 0.024) and OM2
(P = 0.048), but not when compared to HS MM. Again
there were no significant differences between RegES
groups.
The expression of the late osteogenic marker osteocal-
cin was moderate in all of the cell cultures. Mild upre-
gulation of osteocalcin expression by OM3 could be
seen in FBS cultures at day 7, but the difference was not
statistically significant. The elevated expression of osteo-
calcin in FBS OM3 was decreased to basal level by day
14. In RegES medium, the osteocalcin mRNA was
downregulated by OM1, especially at the 14-day time
point, where the level of osteocalcin in OM1 was signifi-
cantly lower than in all the other RegES groups.
Discussion
While the effects of the OM supplements have been lar-
gely studied with BMSCs [15,19-21], there are only lim-
ited studies with ASCs [16,22,39]. One of the major
shortcomings in all of these in vitro studies has been the
lack of comparison between different serum conditions.
Due to quality and safety issues, the clinical hASC-based
applications need to move from the animal-derived pro-
ducts to human-derived or more preferably to defined
and xeno-free conditions [24]. However, most of the in
vitro studies are still conducted using FBS. Given that
the serum conditions can significantly affect the cell
response, it is crucial to obtain research data with more
clinical relevance [26,31].
Accordingly, we aimed to optimize the osteogenic cul-
turing conditions for the in vitro induction of hASCs by
testing different concentrations of Dex and AsA2-P in
HS-based medium as well as in a defined, xeno-free
medium RegES, with FBS medium functioning as a con-
trol. As hypothesized, the differential effect of FBS, HS
or RegES media was evident in hASC proliferation and
osteogenic differentiation. Comparison of the cell
growth in FBS, HS and RegES maintenance media
revealed a slightly higher growth rate in hASCs cultured
in FBS MM than in HS MM, whereas the highest
growth rate was achieved in RegES MM. When compar-
ing MM and OM conditions in general, significantly
higher cell number was achieved in OM than MM parti-
cularly in HS and RegES cultures. The effect of OM in
cell number was also dependent of serum conditions;
under FBS conditions OM3 with the highest AsA2-P
concentration promoted cell growth most, but under HS
conditions both OM2 and OM3 resulted in equally ele-
vated cell numbers. High AsA2-P concentration (250
µM) has been reported to stimulate proliferation of
BMSCs and osteoblast-like cells [21,40], whereas high
Dex concentration (100 nM) may inhibit proliferation
[22]. More importantly, high AsA2-P concentration may
stimulate proliferation without a reciprocal loss of differ-
entiation potency [21,41].
The osteogenic induction capacity of OM1, OM2 and
OM3 was compared by analyzing the ALP activity,
mineralization and relative expression of several osteo-
genic markers. Contrary to expectations, the level of
osteogenic differentiation was the lowest in FBS-cul-
tured hASCs as measured by ALP activity and minerali-
zation. Another significant finding was that the RegES
MM alone was found to induce the early osteogenic dif-
ferentiation as shown by the elevated ALP activity,
although supplementation with Dex, AsA2-P and b-GP
was required to achieve mineralization. On the whole,
the inductive effect of high AsA2-P and low Dex con-
centration, as in OM3, was most evident in HS cultures,
resulting in high ALP activity and mineralization. Prior
studies have noted the importance of AsA2-P in the
osteogenic differentiation of BMSCs and osteoblastic
cells [21,41-43]. In contrast, Dex in high concentrations
has been shown to inhibit osteogenic differentiation
[44,45], although it seems to be necessary for the effi-
cient osteo-induction of MSCs in low concentrations
[15,19,20,44].
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In the present study, variation between donors could
be detected particularly in ALP activity. Under HS and
FBS conditions, two out of three donors exhibited a
notable increase in ALP activity in response to OM2
and OM3, whereas one donor did not seem to respond
to the OM supplements. Donor sample variability affects
the interpretation of the results regardless of analyzing
method and diminishes the statistical significance by
increasing standard deviation. Others have established
this problem previously with ASCs [11,23,46] and
BMSCs [15,47,48]. With BMSCs, Jaiswal and co-workers
showed that the basal level of ALP activity as well as the
timing of the peak ALP activity varied greatly between
the different donor samples irrespective of donor age
[15]. The relative fold induction in ALP activity varied
1.5- to 6.4-fold depending on donor [15]. Similar kind
of variation has been detected with ASCs as well
[11,23,46].
The osteogenic effect of OM1, OM2 and OM3 under
different serum conditions was further studied by ana-
lyzing the relative expression of osteogenic markers,
runx2A, DLX5, collagen type I, osteocalcin and ALP.
Overall, the qRT-PCR data demonstrated significant
upregulation of runx2A mRNA under osteogenic differ-
entiation in FBS and HS medium, and early stimulation
of DLX5 under FBS conditions. The regulation of other
markers, collagen type I, osteocalcin and ALP, was mod-
est. When comparing the different OM compositions,
OM2 and OM3 resulted in significantly higher expres-
sion of runx2A, collagen type I, and ALP, than corre-
sponding MM under FBS or HS conditions. In some
cases, OM2 and OM3 also resulted in higher expression
of runx2A, collagen type I, and ALP than OM1. Under
FBS conditions, OM3 induced significantly higher
expression of runx2A when compared to FBS MM at
day 14. In addition, collagen type I expression was sig-
nificantly upregulated by FBS OM2 and OM3 at day 7
in comparison to both MM and OM1, and versus OM1
on day 14. Under HS conditions, OM3 resulted in sig-
nificantly higher runx2A expression when compared to
HS MM and OM1 at day 7. Moreover, HS OM3
resulted in higher level of ALP expression than OM1
and OM2 on day 14. Hence, greater expression of osteo-
genic markers can be achieved by OM with increased
AsA2-P and lowered Dex, that is OM2 or OM3
composition.
In RegES medium, significant differences in the
runx2A, collagen type I or ALP expression were not
detected, likely due to the high basal level of expression
in RegES MM. However, the level of osteocalcin mRNA
was significantly lower in RegES OM1 than in MM,
OM2 or OM3 at day 14. The expression of DLX5
appeared to peak already on day 7 under osteogenic
induction under FBS conditions, whereas no regulation
of DLX5 was detected under HS and RegES conditions.
There were also notable differences in the collagen
type I and ALP mRNA expression between the serum
conditions in general. The expression of collagen type I
was notably lower in all RegES groups when compared
to the respective FBS and HS groups. The expression of
ALP, on the contrary, was higher in the RegES groups
than in FBS and HS groups. This result correlates with
the high ALP protein activity in RegES cultures, but in
turn, not with the high ALP activity found in HS cul-
tures. Unexpectedly, the expression of runx2, collagen
type I, ALP or osteocalcin was not upregulated by time
(day 7 versus 14) in any of the OM groups. Although
we did not see significant upregulation by time, the cul-
ture period of 14 days has been shown to be sufficient
for the detection of osteogenic gene expression [49-51].
Furthermore, considering clinical applications, the in
vitro culture period should be minimized, as prolonged
culture may increase the risk of contamination or
genetic abnormalities. Therefore, the inductive effects in
vitro should also appear within as short a time period as
possible.
In contrast to ALP activity and mineralization, rela-
tively small changes were detected in mRNA expression
levels between MM and OM groups under all serum
conditions. Although challenging the common concep-
tion, the lack of upregulation or even downregulation of
certain osteogenic markers in ASCs upon osteogenic dif-
ferentiation has been reported previously [12,18]. For
OM-induced BMSCs, similar differences have been
reported between the data obtained on protein level and
real-time PCR for collagen type I expression [52]. The
flow cytometric analysis showed significantly upregu-
lated expression of collagen type I in the ECM of differ-
entiated BMSCs, but there was no notable increase in
collagen type I mRNA even after osteogenic differentia-
tion according to real-time PCR [52]. While this phe-
nomenon is still poorly understood, it is evident that the
route of mRNA to protein is a highly regulated and
complex pathway, where even small changes at tran-
scriptional or posttranscriptional level can have a major
phenotypic effect [12,18,53].
One of the main scopes of the present study was to
investigate whether xeno-free RegES medium could be uti-
lized for the efficient osteogenic differentiation of hASCs.
Taken together, hASCs cultured in RegES showed
increased osteogenic capacity, an effect likely explained by
the composition of the RegES medium (Additional file 1).
Apart from the several growth factors and cytokines, the
high concentration of AsA2-P in RegES MM (50 µg/ml or
170 µM) may account for the high basal level of cell
growth and osteogenic differentiation of hASCs in the
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plain RegES medium. Taking into account the additional
AsA2-P in the osteogenic media, the concentrations in
RegES OM1, OM2 and OM3, raised to 220, 320, and 420
µM, respectively. The maximal advantage in growth rate
and differentiation in RegES-based osteogenic media was
reached by AsA2-P concentrations varying from 220 to
320 µM, correlating to the results obtained with OM3
under FBS and HS conditions. However, as already men-
tioned, supplementation with Dex and b-GP in addition to
AsA2-P was required for efficient osteo-induction and
maturation of hASCs cultured in RegES.
Conclusions
In summary, our results show that the serum conditions
have a significant effect on the hASC behavior, such as
proliferation and osteogenic differentiation capacity.
Osteogenic differentiation of hASCs was the weakest in
FBS-based medium. The plain RegES medium was able
to induce early osteogenic differentiation of hASCs,
although supplementation with Dex, AsA2-P and b-GP
was needed to achieve mineralization. One of the key
findings was that the commonly used OM1 supports the
in vitro osteo-induction of hASCs poorly in FBS and HS
medium. Instead, OM with higher AsA2-P and lower
Dex should be used for the osteogenic differentiation of
hASCs under FBS and HS conditions.
Additional material
Additional file 1: RegES medium. Complete formulation for RegES
medium.
Additional file 2: Preliminary screening. Osteogenic medium (OM)
compositions of the preliminary screening (all in HS medium).
Additional file 3: Cell morphology at different time points. Light
microscope images showing representative hASC morphology in each
maintenance medium at 3-, 7- and 14-day time points. Scale bar 500 µm.
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